OLLIE integrates with Pleio’s GoodStart program and supports pharmaceutical companies in earlier identification and understanding of patient sentiment and confidence
With nearly half of all patients discontinuing their prescribed medications within a year, the key to improving adherence isn’t replacing human connection — it’s strengthening it. Pleio, the peer-to-patient platform that powers a human-first approach, launches OLLIE™, an AI-powered solution designed to deepen patient engagement, empower individuals from day one, and lay the foundation for lasting behavioral treatment success.
OLLIE is centered around the patient experience, listening, understanding, and guiding patient conversations. By analyzing these authentic interactions, OLLIE delivers critical information about patient sentiment, confidence levels, and emotional barriers that impact medication adherence — a challenge that contributes to up to 69% of all medication-related hospitalizations in the U.S. This AI-driven approach propels the patient experience forward, ensuring that every interaction is delivered with minimal friction in a meaningful, impactful, and relevant way with human touch at the forefront.
Pleio’s GoodStart™ program provides human-centric support to patients starting new medications. GoodStarters are highly trained peers in the community who speak directly with patients in a scripted environment. Conversations support and encourage patients with knowledge and skills in medication management. Now, OLLIE works behind the scenes during these conversations, picking up on subtle indicators to further enhance engagement.
“Pleio’s GoodStarters are already highly trained, empathetic peers who connect with patients in a way that truly matters,” said Michael Oleksiw, CEO at Pleio. “OLLIE takes that to the next level — it’s human connection, amplified — technology that makes our people even better at what they do best.”
Also Read: VisiQuate Acquires Rotera to Boost AI Revenue Automation
At the core of OLLIE’s capabilities is its ability to decode the human side of patient interactions, uncovering raw emotional reactions that may otherwise go unnoticed. These AI-powered insights ensure patient engagement opportunities are hyper-personalized, effective, and compliant with pharmaceutical industry standards.
OLLIE addresses critical gaps in understanding patient experiences by focusing on the overall patient vibe, friction points, tipping points, and preferences — key behavioral indicators that shape prescription decisions and adherence. Pleio captures vibe as the emotional state and atmosphere within patient interactions, revealing underlying attitudes, concerns, and levels of confidence in treatment. By identifying barriers to engagement and recognizing the moments that drive behavioral shifts, OLLIE transforms real conversational data into actionable insights. These nuances are then used to define patient personas based on real conversational data.
“Rapid advancements in AI transform how we connect with patients,” said Martin Robert, Chief Product Officer at Pleio. “While technology plays a crucial role, human connection remains at the heart of meaningful support. OLLIE listens and analyzes patient conversations in order to better understand the patient experience. These insights are then used to create, deliver, and report upon our proven GoodStart programs, ensuring every interaction builds trust, confidence, and support for patients.”
Source: PRNewswire
